Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke
Di Yu,Nuanyi Liang,Julia Zebarth,Qing Shen,Miracle Ozzoude,Maged Goubran,Jennifer S. Rabin,Joel Ramirez,Christopher J. M. Scott,Fuqiang Gao,Robert Bartha,Sean Symons,Seyyed Mohammad Hassan Haddad,Courtney Berezuk,Brian Tan,Donna Kwan,Robert A. Hegele,Allison A. Dilliott,Nuwan D. Nanayakkara,Malcolm A. Binns,Derek Beaton,Stephen R. Arnott,Jane M. Lawrence‐Dewar,Ayman Hassan,Dar Dowlatshahi,Jennifer Mandzia,Demetrios Sahlas,Leanne Casaubon,Gustavo Saposnik,Yurika Otoki,Krista L. Lanctôt,Mario Masellis,Sandra E. Black,Richard H. Swartz,Ameer Y. Taha,Walter Swardfager,Natalie Rashkovan,Sandra E. Black,Agessandro Abrahao,Lorne Zinman,Alisia Bonnick,Richard H. Swartz,Mario Masellis,Joel Ramirez,Christopher Scott,Sean Symons,Courtney Berezuk,Melissa Holmes,Sabrina Adamo,Miracle Ozzoude,Morris Freedman,Brian Tan,Mojdeh Zamyadi,Stephen Arnott,Derek Beaton,Malcolm Binns,Pradeep Raamana,Stephen Strother,Kelly Sunderland,Athena Theyers,Abiramy Uthirakumaran,Brian Levine,Angela Troyer,Michael Strong,Peter Kleinstiver,Michael Borrie,Elizabeth Finger,Christen Shoesmith,Frederico Faria,Manuel Montero‐Odasso,Yanina Sarquis‐Adamson,Alanna Black,Jennifer Mandzia,Allison Ann Dilliott,Rob Hegele,John Robinson,Sali Farhan,Rob Bartha,Hassan Haddad,Nuwan Nanayakkara,Guangyong Zou,Stephen Pasternak,JB Orange,Angela Roberts,Mandar Jog,Dallas Seitz,Don Brien,Ying Chen,Brian Coe,Doug Munoz,Paula McLaughlin,Alicia Peltsch,Donna Kwan,Susan Bronskill,Wendy Lou,Sanjeev Kumar,Bruce Pollock,Tarek Rajji,David Tang‐Wai,Carmela Tartaglia,Brenda Varriano,Marvin Chum,John Turnbull,Jane Lawrence‐Dewar,Ayman Hassan,Julia Fraser,Bill McIlroy,Ben Cornish,Karen Van Ooteghem,Chris Hudson,Elena Leontieva,Wendy Hatch,Faryan Tayyari,Sherif Defrawy,Edward Margolin,Efrem Mandelcorn,Barry Greenberg,Leanne Casaubon,Anthony Lang,Connie Marras,Andrew Frank,Dar Dowlatshahi,David Grimes,Dennis Bulman,John Woulfe,Mahdi Ghani,Demetrios Sahlas,Gustavo Saposnik,Tom Steeves,David Munoz,Corinne Fischer,Ekaterina Rogaeva,Sujeevini Sujanthan,David Breen,Roger A. Dixon
DOI: https://doi.org/10.1161/JAHA.122.026901
2023-01-01
Abstract:Background Cerebral small vessel disease is associated with higher ratios of soluble‐epoxide hydrolase derived linoleic acid diols (12,13‐dihydroxyoctadecenoic acid [DiHOME] and 9,10‐DiHOME) to their parent epoxides (12(13)‐epoxyoctadecenoic acid [EpOME] and 9(10)‐EpOME); however, the relationship has not yet been examined in stroke. Methods and Results Participants with mild to moderate small vessel stroke or large vessel stroke were selected based on clinical and imaging criteria. Metabolites were quantified by ultra‐high‐performance liquid chromatography–mass spectrometry. Volumes of stroke, lacunes, white matter hyperintensities, magnetic resonance imaging visible perivascular spaces, and free water diffusion were quantified from structural and diffusion magnetic resonance imaging (3 Tesla). Adjusted linear regression models were used for analysis. Compared with participants with large vessel stroke (n=30), participants with small vessel stroke (n=50) had a higher 12,13‐DiHOME/12(13)‐EpOME ratio (β=0.251, P =0.023). The 12,13‐DiHOME/12(13)‐EpOME ratio was associated with more lacunes (β=0.266, P =0.028) but not with large vessel stroke volumes. Ratios of 12,13‐DiHOME/12(13)‐EpOME and 9,10‐DiHOME/9(10)‐EpOME were associated with greater volumes of white matter hyperintensities (β=0.364, P <0.001; β=0.362, P <0.001) and white matter MRI‐visible perivascular spaces (β=0.302, P =0.011; β=0.314, P =0.006). In small vessel stroke, the 12,13‐DiHOME/12(13)‐EpOME ratio was associated with higher white matter free water diffusion (β=0.439, P =0.016), which was specific to the temporal lobe in exploratory regional analyses. The 9,10‐DiHOME/9(10)‐EpOME ratio was associated with temporal lobe atrophy (β=−0.277, P =0.031). Conclusions Linoleic acid markers of cytochrome P450/soluble‐epoxide hydrolase activity were associated with small versus large vessel stroke, with small vessel disease markers consistent with blood brain barrier and neurovascular‐glial disruption, and temporal lobe atrophy. The findings may indicate a novel modifiable risk factor for small vessel disease and related neurodegeneration. Clinical Perspective What Is New? In clinical stroke, linoleic acid markers of cytochrome P450/soluble‐epoxide hydrolase activity in peripheral blood were higher in people with small vessel versus large vessel etiology. On imaging, these blood markers were associated with the extent of cerebral small vessel disease (volumes of white matter hyperintensities and perivascular spaces), markers of blood brain barrier disruption (white matter free water), and temporal lobe atrophy. What Are the Clinical Implications? This lipid pathway represents a novel modifiable risk factor and may offer new potential to track and treat small vessel stroke and related neurodegeneration. Nonstandard Abbreviations and Acronyms CYP450 cytochrome P450 FW free water diffusion LVS large vessel stroke LA linoleic acid PVS MRI‐visible perivascular space ONDRI Ontario Neurodegenerative Initiative SVS small vessel stroke/lacunar stroke sEH soluble epoxide hydrolase WMH white matter hyperintensity Ischemic stroke is heterogeneous, involving divergent contributing causes, risk factors, and underlying etiopathologies. Two common ischemic stroke subtypes involve small vessel occlusion and large‐artery stenosis producing symptoms. 1 Small vessel stroke (SVS) is defined by subcortical infarcts (lacunes), with other markers of cerebral small vessel disease including white matter hyperintensities (WMH), microbleeds, and enlarged magnetic resonance imaging (MRI)‐visible perivascular spaces (PVS) 2 ; however, these features are also found commonly in people who present clinically with large vessel stroke (LVS). These pathological overlaps and heterogeneities complic -Abstract Truncated-